A Phase Ib/II, Multicentre, Open Label, Randomised Study of BI 836845 in Combination with Enzalutamide, versus Enzalutamide alone, in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Following Disease Progression on Docetaxel-Based Chemotherapy and Abiraterone. Protocol 1280.8
The purpose of this study is to test the safety, tolerability and effects of the study drug, called BI 836845, when used with along with enzalutamide. Enzalutamide is already approved by the US Food and Drug Administration (FDA) for use in prostate cancer. The use of the study drug is experimental. It has not been approved by the FDA.
Metastatic Castrate Resistant Prostate Cancer (mCRPC)
- Metastatic prostate cancer that no longer responds to standard androgen deprivation therapy
- Currently receiving enzalutamide, but cancer returning in spite of enzalutamide therapy
- have a metastatic lesion that is able to be biopsied
18 - NA
Healthy Volunteers Needed
Duration of Participation
Approximately 10-12 months
Clinical Trials Information Line: Phone 503-494-1080 or firstname.lastname@example.org
Boehringer Ingelheim Pharmaceuticals, Inc.